NICE says prescribe statins to everyone with chronic kidney disease

NICE says prescribe statins to everyone with chronic kidney disease

August 3 2017 NICE has released a new Quality Standard listing atorvastatin “as the...

NOACs compare favourably to warfarin in new studies

NOACs compare favourably to warfarin in new studies

June 22 2016 Two BMJ studies have further supported the use of alternatives to warfarin for...

Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

May 11 2016 Serious health risks in type 2 diabetes may be reduced more effectively with insulin...

Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

April 27 2016 Methotrexate in combination with sulphasalazine and hydroxychloroquine has been...

SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

April 20 2016 Patients taking sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin,...

  • NICE says prescribe statins to everyone with chronic kidney disease

    NICE says prescribe statins to everyone with chronic kidney disease

    Saturday, 05 August 2017 13:27
  • NOACs compare favourably to warfarin in new studies

    NOACs compare favourably to warfarin in new studies

    Wednesday, 22 June 2016 14:14
  • Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

    Insulin used with metformin appears more protective than insulin alone in type 2 diabetes

    Wednesday, 11 May 2016 14:15
  • Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

    Cheaper options for methotrexate/DMARD combination for rheumatoid arthritis proposed

    Wednesday, 27 April 2016 13:22
  • SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

    SGLT2 and diabetic ketoacidosis risk among MHRA drug safety updates

    Wednesday, 20 April 2016 13:25

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

heart failureJune 22 2016

Two BMJ studies have further supported the use of alternatives to warfarin for anticoagulation needs in atrial fibrillation.

Overall, novel oral anticoagulants (NOACs) are not significantly different to warfarin in terms of risk of ischaemic stroke, but rivaroxaban was associated with a lower risk of ischaemic stroke or systemic embolism compared to warfarin, although with comparable major bleeding rates.

Meanwhile, “dabigatran and apixaban had non-significant hazard ratios compared with warfarin for ischaemic stroke or systemic embolism, whereas major bleeding rates were significantly lower with reference to warfarin.”

A study on the effects of polypharmacy in atrial fibrillation found that “apixaban was more effective than warfarin regardless of the number of concomitant drugs used.” Apibaxan also had lower bleeding rates compared to warfarin, although the researchers concluded that the size of benefit appeared to decrease as the number of concomitant medicines the patient was taking increased.

The studies, one based at Aalborg University, Denmark, and the other based at a number of centres around the world, had been assessing risks associated with NOACs.

The Danish study looked at the effectiveness and safety of the NOAC non-vitamin K antagonist oral anticoagulants dabigatran, rivaroxaban, and apixaban in comparison with warfarin in patients with atrial fibrillation who had not been given an anticoagulant previously. Outcomes were measured by ischaemic stroke, systemic embolism as well as bleeding.

Data from over 61,000 patients with non-valvular atrial fibrillation was analysed. NOACs were not significantly different to warfarin when the analysis was restricted to ischaemic stroke. However, “during one year follow-up, rivaroxaban was associated with lower annual rates of ischaemic stroke or systemic embolism (3.0% v 3.3%, respectively) compared with warfarin: hazard ratio 0.83 (95% confidence interval 0.69 to 0.99).”

The annual hazard ratios for dabigatran was 2.8% and for apixaban was 4.9%, although this was non-significant compared to warfarin. “The annual risk of death was significantly lower with apixaban (5.2%) and dabigatran (2.7%) (0.65, 0.56 to 0.75 and 0.63, 0.48 to 0.82, respectively) compared with warfarin (8.5%), but not with rivaroxaban (7.7%).”

The researchers concluded: “All NOACs seem to be safe and effective alternatives to warfarin in a routine care setting.” While there were no significant differences between NOACs and warfarin for ischaemic stroke, “the risks of death, any bleeding, or major bleeding were significantly lower for apixaban and dabigatran compared with warfarin.”

The second study looking at polypharmacy was part of the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. The multicentre study ran for five years from 2006 to 2011 and included 18,201 patients who either received apixaban 5mg twice daily or took warfarin with a target INR of 2.0 to 3.0.

Patients were also assessed for other treatment being used, and the median of taking six medicines was seen in almost 14,000 patients. Co-morbidities increased with increasing number of medicines taken, “as did the proportions of patients treated with drugs that interact with warfarin or apixaban.

“Mortality also rose significantly with the number of drug treatments (P<0.001), as did rates of stroke or systemic embolism (1.29, 1.48, and 1.57 per 100 patient years, for 0-5, 6-8, and ≥9 drugs, respectively) and major bleeding (1.91, 2.46, and 3.88 per 100 patient years, respectively).”

The researchers found a consistent relative risk reduction in stroke or systemic embolism for apibaxan compared to warfarin, regardless of the number of drugs being taken. There was also a small but significant reduction in major bleeding.

“In terms of a potential differential response to anticoagulation therapy in patients with atrial fibrillation and polypharmacy, apixaban was more effective than warfarin, and is at least just as safe,” concluded the researchers.

Links:

JJ Focks et al. ‘Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial’. BMJ 2016;353:i2868

TB Larsen et al. ‘Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study’. BMJ 2016;353:i3189.

Clinical News

August 18 2017 LloydsPharmacy has announced that it will shoulder the 5% VAT cost on sanitary products, the so-called ‘tampon tax’.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...